The efficacy of citalopram or escitalopram in patients with asthma and major depressive disorder.
Journal
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
ISSN: 1534-4436
Titre abrégé: Ann Allergy Asthma Immunol
Pays: United States
ID NLM: 9503580
Informations de publication
Date de publication:
11 Nov 2023
11 Nov 2023
Historique:
received:
29
05
2023
revised:
07
11
2023
accepted:
07
11
2023
pubmed:
13
11
2023
medline:
13
11
2023
entrez:
12
11
2023
Statut:
aheadofprint
Résumé
Major depressive disorder is common in people with asthma. Yet, few studies have evaluated depression treatment in those with asthma. To explore the relationship between antidepressant use, depressive symptoms, and asthma control, pooled data from 3 randomized trials of either citalopram or escitalopram were assessed. Linear fixed effects and binary logistic regression analyses were conducted with between-subject covariates including treatment group, (original) study, and demographics. The within-subject effect of visit, and a treatment group-visit (between-within) interaction effect, were also evaluated. Analyses were repeated in a high asthma exacerbation subgroup having at least 3 oral corticosteroid bursts in the previous 12 months. Outcomes included the Hamilton rating scale for depression (HAM-D In the pooled sample (n = 255), the antidepressant treatment group exhibited lower HAM-D Citalopram or escitalopram exhibited efficacy in reducing depressive symptoms and the need for rescue oral corticosteroids in patients with asthma and major depressive disorder. Future work should determine whether selective serotonin reuptake inhibitors are effective at improving asthma outcomes in those with asthma who are not depressed. Clinicaltrials.gov Identifier: NCT00621946 and NCT01324700 (one study was conducted before ClinicalTrials.gov requirements).
Sections du résumé
BACKGROUND
BACKGROUND
Major depressive disorder is common in people with asthma. Yet, few studies have evaluated depression treatment in those with asthma.
OBJECTIVE
OBJECTIVE
To explore the relationship between antidepressant use, depressive symptoms, and asthma control, pooled data from 3 randomized trials of either citalopram or escitalopram were assessed.
METHODS
METHODS
Linear fixed effects and binary logistic regression analyses were conducted with between-subject covariates including treatment group, (original) study, and demographics. The within-subject effect of visit, and a treatment group-visit (between-within) interaction effect, were also evaluated. Analyses were repeated in a high asthma exacerbation subgroup having at least 3 oral corticosteroid bursts in the previous 12 months. Outcomes included the Hamilton rating scale for depression (HAM-D
RESULTS
RESULTS
In the pooled sample (n = 255), the antidepressant treatment group exhibited lower HAM-D
CONCLUSION
CONCLUSIONS
Citalopram or escitalopram exhibited efficacy in reducing depressive symptoms and the need for rescue oral corticosteroids in patients with asthma and major depressive disorder. Future work should determine whether selective serotonin reuptake inhibitors are effective at improving asthma outcomes in those with asthma who are not depressed.
TRIAL REGISTRATION
BACKGROUND
Clinicaltrials.gov Identifier: NCT00621946 and NCT01324700 (one study was conducted before ClinicalTrials.gov requirements).
Identifiants
pubmed: 37952772
pii: S1081-1206(23)01401-1
doi: 10.1016/j.anai.2023.11.004
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT00621946', 'NCT01324700']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosures The authors declare no conflicts of interest.